Frontlight ResearchEarly access
Taking peoplePhase 2
Scan imaging of immune cells in arteries of people with giant cell arteritis
Tests a PET scan tracer in adults with active large vessel giant cell arteritis.
Key facts
- Who runs it
- Universitair Medisch Centrum Groningen
- Where
- Netherlands2 sites in 1 countryChoose a country to see its sites
- Registry title
- Macrophage imaging GCA
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 10 people, planned
- Started
- 12 Nov 2024
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional
- Record updated
- 11 September 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with active giant cell arteritis of the large blood vessels. They get a PET/CT scan with [18F]fluor-PEG-folate, and again after 9 months of standard treatment.
- Age
- 50 years or older when the disease started (the record lists 18 Years as the minimum age).
- Sex
- All sexes. Women who could become pregnant cannot join.
- Disease stage
- Active large vessel giant cell arteritis. People need at least one symptom now: tiredness, fever, weight loss or night sweats, limb pain on walking, or shoulder or hip pain with morning stiffness. Scans (for example ultrasound or FDG-PET/CT) must show large vessel disease.
- Earlier treatment
- No start or dose increase of steroid tablets or injections in the 4 weeks before joining. No start or dose increase of DMARDs (disease-modifying antirheumatic drugs) in the 3 months before. No trial drug in the 3 months before.
- Biomarker or test result
- ESR (blood sedimentation rate) of 50 mm/hr or more, or CRP of 10 mg/L or more.
Main reasons for not taking part
- Signs of giant cell arteritis in the head, such as a new headache, a tender scalp, jaw pain when chewing, vision loss or stroke
- Ultrasound signs of arteritis in the head arteries, or an earlier positive temporal artery biopsy
- Women who could become pregnant (women with no periods for more than 12 months can join)
- Radiation from research of 5 mSv or more in total in the past year
- Recent new or higher doses of steroids, DMARDs or trial drugs
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Age ≥ 50 years at time of disease onset - Erythrocyte sedimentation rate (ESR) ≥50 mm/hr or C-reactive protein (CRP) ≥ 10 mg/L - Clinical symptoms of large vessel GCA (at least one of the following) at time of inclusion: constitutional symptoms (fatigue, fever, weight loss, and/or night sweats), limb claudication, or symptoms of polymyalgia rheumatica (i.e. shoulder and/or hip girdle pain associated with morning stiffness). - Imaging findings consistent with large vessel GCA at the time of inclusion (e.g. ultrasound, FDG-PET/CT) - Patients must be able to adhere to the study appointments and other protocol requirements. - Patients must be capable of giving informed consent and the consent must have been obtained prior to the study related procedures
Who cannot take part
- Clinical symptoms suggestive of cranial GCA (at least one of the following): new-onset localized headache, scalp tenderness, temporal artery abnormality (thickening, tenderness, and/or decreased pulsation), ischemia-related vision loss, stroke, transients ischemic attack, jaw or tongue claudication (pain upon mastication). - Ultrasound findings consistent with cranial GCA (e.g. halo sign in temporal or facial artery). - A prior positive temporal artery biopsy. - Initiation or dose escalation of systemic glucocorticoid therapy (oral, IM, IV) in the 4 weeks prior to inclusion - Initiation or dose escalation of disease-modifying antirheumatic drugs (DMARDs) within 3 months prior to inclusion - Treatment with any investigational drug within 3 months prior to inclusion. - Females with child bearing potential. Post-menopausal women with >12 months of amenorrhoea are considered to have no child bearing potential. Given the age distribution of patients with GCA, exclusion of females with child bearing potential will not lead to recruitment bias in the study. - Research-related radiation exposure (cumulative ≥5 mSv) in the year before inclusion
This trial is currently available in Netherlands.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Primary Objective: to evaluate arterial [18F]fluor-PEG-folate uptake on PET/CT in patients with active, large vessel GCA; and in the same patients after 9 months of standard treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- [18F]fluor-PEG-folate PET/CT imaging in giant cell arteritis: a pilot study
- Plain-language title
- Scan imaging of immune cells in arteries of people with giant cell arteritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 11 September 2024